Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
197.84(c) 202.47(c) 199.19(c) 208.24(c) 221.36(c) Last
7 264 747 4 955 160 6 663 813 7 423 063 10 066 344 Volume
-1.86% +2.34% -1.62% +4.54% +6.30% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 18 632 M - -
Net income 2021 10 719 M - -
Net cash position 2021 11 520 M - -
P/E ratio 2021 8,97x
Yield 2021 -
Sales 2022 15 883 M - -
Net income 2022 7 395 M - -
Net cash position 2022 20 906 M - -
P/E ratio 2022 12,5x
Yield 2022 -
Capitalization 88 882 M 88 882 M -
EV / Sales 2021 4,15x
EV / Sales 2022 4,28x
Nbr of Employees 1 300
Free-Float 90,3%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
More about the company
Ratings of Moderna, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about MODERNA, INC.
07:18aGSK's drugs arm to get $11 billion windfall from consumer spin-off
RE
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
AQ
01:02aSECTORAL ASSET MANAGEMENT  : Covid-Vaccine Patent Waiver: Will it Increase World..
DJ
06/22MODERNA  : B.C. health officials say mixing mRNA vaccines is safe, effective
AQ
06/22Nasdaq hits record high as Big Tech roars back
RE
06/22MODERNA  : president talks COVID-19 and vaccine technology
AQ
06/22MODERNA  : European Commission Purchases Additional 150 Million Doses of Moderna..
BU
06/22MODERNA  : to Supply Additional 150 Million Doses of COVID-19 Vaccine to Europea..
MT
06/22Today on Wall Street: The investor dilemma
06/22MODERNA  : Doctors Without Borders (MSF) responds to mRNA COVID vaccine technolo..
AQ
06/22MODERNA  : European Commission To Buy Additional 150 Million COVID-19 Vaccine Sh..
MT
06/22MODERNA  : Doctors Without Borders (MSF) responds to mRNA COVID vaccine technolo..
AQ
06/22MARKET CHATTER : SK Bioscience to Invest $132 Million in Expansion of COVID-19 V..
MT
06/21U.S. administers more than 318 mln doses of COVID-19 vaccines - CDC
RE
06/21MODERNA  : U.S. CDC Says Administered 318,576,441 Doses Of Covid-19 Vaccine As O..
RE
More news
News in other languages on MODERNA, INC.
06:25aCOVID  : 15,3 mln dosi Pfizer e Moderna a giugno, 14,5 mln a luglio
01:02aSECTORAL ASSET MANAGEMENT  : Covid-Impfstoff-Patentverzicht - wird er den weltwe..
06/22WALL STREET STOCK EXCHANGE : Wall Street finit en hausse, la "tech" porte le Nas..
06/22CORONA-BLOG/USA werden 70-Prozent-Ziel bei Impfungen zum 4. Juli verpassen
06/22CORONA-BLOG/EU-Kommission gibt Italien grünes Licht für massive Corona-Hilfen
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 221,36 $
Average target price 168,87 $
Spread / Average Target -23,7%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
IQVIA HOLDINGS INC.36.17%46 761
CELLTRION, INC.-23.68%32 903
SEAGEN INC.-9.40%28 797
HANGZHOU TIGERMED CONSULTING CO., LTD22.21%25 469